# Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer

> **NCT00673829** · PHASE1 · SUSPENDED · sponsor: **Roger Williams Medical Center** · enrollment: 26 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** Gene Modified T Cells
- **BIOLOGICAL:** Gene Modified T Cells and Interleukin 2

## Key facts

- **NCT ID:** NCT00673829
- **Lead sponsor:** Roger Williams Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2008-05
- **Primary completion:** 2017-12
- **Final completion:** 2018-12
- **Target enrollment:** 26 (ESTIMATED)
- **Why stopped:** Funding
- **Last updated:** 2016-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00673829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00673829, "Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00673829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*